CD2BP2-DT

Across TCGA pan-cancer cohorts, CD2BP2-DT RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated CD2BP2-DT data layer.

The strongest signal is observed in mesothelioma (MESO), where higher CD2BP2-DT RNA is associated with better overall survival. In most high-consensus cancer types, elevated CD2BP2-DT expression acts as an unfavorable survival marker, although some lineages such as MESO and LUAD show a favorable association.

MESO, UVM, and LUAD are the cancer types where CD2BP2-DT RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.699	0.389	<.001	89	view →
UVM	DFS	Quartile	All	0.422	0.837	.003	45	view →
LUAD	OS	Quartile	II,III,IV	0.668	0.436	.004	44	view →
BRCA	OS	Median	All	0.947	0.901	.001	43	view →
LGG	OS	Median	All	0.856	0.932	<.001	31	view →
ACC	DFS	Median	II,III,IV	0.242	0.766	.002	19	view →
CESC	OS	Median	II,III,IV	0.773	0.370	.002	18	view →
SKCM	OS	Quartile	II,III,IV	0.549	0.244	.001	17	view →
DLBC	DFS	Tertile	All	0.752	0.335	.008	15	view →
PAAD	DFS	Median	All	0.397	0.609	.006	14	view →
PRAD	DFS	Median	All	0.921	0.850	.009	12	view →
READ	OS	Quartile	II,III,IV	0.863	0.369	.008	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

CD2BP2-DT–MESO (OS)

Open the MESO breakdown →